9 Biotech Stocks With Insider Buying
Contextuall | Dec 14, 2012 03:07AM ET
:
All of these Biotech stocks have seen significant buying from company insiders.
Average Weekly Returns:
Average 1-Week Return of All Stocks Mentioned Below: 2.85%
Average 1-Month Return of All Stocks Mentioned Below: 19.41%
Analysis of List Alpha:
Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Week): 4 out of 9 (44.44%)
Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Month): 9 out of 9 (100.0%)
Chart: Distribution of 1-Week Returns For All Stocks Mentioned Below
Chart: Distribution of 1-Month Returns For All Stocks Mentioned Below
1. Pacific Biosciences of California, Inc. (PACB): Develops, manufactures, and markets an integrated platform for genetic analysis. Net insider purchases at 400,000 shares over the last six months, vs. a float of 29.86M shares (1.34% of total float).
2. China Biologic Products, Inc. (CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. Net insider purchases at 1,620,360 shares over the last six months, vs. a float of 6.28M shares (25.80% of total float).
3. Infinity Pharmaceuticals, Inc. (INFI): Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States. Net insider purchases at 5,158,726 shares over the last six months, vs. a float of 22.15M shares (23.29% of total float).
4. Amicus Therapeutics, Inc. (FOLD): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Net insider purchases at 2,949,580 shares over the last six months, vs. a float of 24.73M shares (11.93% of total float).
5. Halozyme Therapeutics, Inc. (HALO): Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. Net insider purchases at 1,307,690 shares over the last six months, vs. a float of 61.98M shares (2.11% of total float).
6. Amyris, Inc. (AMRS): Amyris, Inc., an integrated renewable products company, offers renewable compounds for a variety of markets. Net insider purchases at 2,288,360 shares over the last six months, vs. a float of 28.18M shares (8.12% of total float).
7. PROLOR Biotech, Inc. (PBTH): Engages in the development of proprietary versions of already-approved therapeutic proteins. Net insider purchases at 1,005,000 shares over the last six months, vs. a float of 35.86M shares (2.80% of total float).
8. Theravance Inc. (THRX): Engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Net insider purchases at 9,974,883 shares over the last six months, vs. a float of 54.52M shares (18.30% of total float).
9. Repros Therapeutics Inc. (RPRX): Net insider purchases at 557,500 shares over the last six months, vs. a float of 12.72M shares (4.38% of total float).
Get The News You Want
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.